You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

194 Results
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    fedratinib - For the treatment of splenomegaly and/or disease related symptoms of myelofibrosis according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
fedratinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma
ODB - General Benefit
    capecitabine
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
oxaliplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
The cervical screening test checks for types of human papillomavirus (HPV) that can sometimes cause cervical cancer. It also checks for cell changes...
A wide range of cancer screening, diagnostic and treatment services is available at cancer centres, hospitals and clinics throughout Ontario. Some of...
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
zolbetuximab,
oxaliplatin,
capecitabine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Guidelines and Advice
Status: In-Review
ID: RR SCT-9
Version: N/A
Jun 2020
Guidelines and Advice
Status: In-Review
ID: 26-4
Jun 2015
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2025
Guidelines and Advice
Status: Current
ID: 4-16
Version: 2
Updated
May 2025

Pages